Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Unified agenda

This article was originally published in The Tan Sheet

Executive Summary

FDA will announce a Notice of Proposed Rulemaking in June on "the use of stimulant active ingredients to relieve symptoms associated with a hangover" in OTC products, the agency announces in HHS' semi-annual "unified agenda." The document, which was published in the Federal Register April 24, also notes that final action is slated for December on a proposal to require additional warnings for OTC bronchodilators containing ephedrine or epinephrine. The proposed amendment was issued by FDA in July (1"The Tan Sheet" July 18, 2005, p. 10). FDA also expects to take final action in August on a proposed rule to allow new indications for bismuth subsalicylate products. The proposal was announced in January 2005 (2"The Tan Sheet" Jan. 10, 2005, p. 7)...

You may also be interested in...



OTC Bronchodilators With Ephedrine Permitted In New Proposed Rule

Additional warnings and other revised labeling would be required for bronchodilator products containing ephedrine or epinephrine under an FDA proposed rule published in the July 13 Federal Register

Overindulgence TFM Gets Bloated With Belching, Gas Indications

FDA will allow for the inclusion of two new indications for bismuth subsalicylate products, according to a proposed amendment to the overindulgence Tentative Final Monograph in the Jan. 5 Federal Register

Cybersecurity: Guidance Docs To Come, But Legacy Devices Still A Challenge

Increasing savvy around cybersecurity issues is driving regulators and trade groups to update their approach to the area, speakers from the US FDA and the American Medical Association said at this week’s FDA/CMS Summit.

Topics

UsernamePublicRestriction

Register

PS099336

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel